



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/894,156	08/15/1997	BERND BRUCHMANN	524-2769-0	8696
22850	7590 09/09/2003		Ž	96
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			EXAMINER	
	940 DUKE STREET ALEXANDRIA, VA 22314		SERGENT, RABON A	
			ART UNIT	PAPER NUMBER
			1711	
			DATE MAILED: 09/09/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

,		N				
	Application No.	Applicant(s)				
•	08/894,156	BRUCHMANN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Rabon Sergent	1711				
The MAILING DATE of this communication appears on the cover sheet with the correspond nce address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by states and the period for reply will, by states and patent term adjustment. See 37 CFR 1.704(b). Status	N. R 1.136(a). In no event, however, may a report of thirty rippers of the statutory minimum of thirty rippers of the statutory of the statu	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 1	10 June 2003					
<u> </u>	This action is non-final.					
3) Since this application is in condition for allo		ers, prosecution as to the merits is				
closed in accordance with the practice und Disposition of Claims						
4)⊠ Claim(s) <u>1-5 and 8-18</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-5,8-11 and 13-17</u> is/are rejected.						
7)⊠ Claim(s) <u>12 and 18</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120	-iiikd 25 H 0 0 .C	440(-) (-) (5)				
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of:						
<u> </u>	1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)	, , , , , , , , , , , , , , , , , , , ,	·•				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of In:	ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)				

Application/Control Number: 08/894,156 Page 2

Art Unit: 1711

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

2. Claims 1-5, 8-11, and 13-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mohring et al. ('350 or '936) in view of Wagner et al. ('127 or '622) and Hennig et al. ('956).

Mohring et al. disclose the production of biuret containing polyisocyanates having a low unreacted polyisocyanate monomer content and light color, wherein diisocyanates are reacted with an alcohol component, including tertiary alcohols; an amine component; and water. See column 3, lines 10+ and columns 4-7.

Application/Control Number: 08/894,156 Page 3

Art Unit: 1711

- 3. While Mohring et al. disclose the use of amines, patentees fail to disclose the use of applicants' claimed nitrogen containing stabilizer. However, applicants' claimed stabilizers were known at the time of invention to be useful agents for the production of biurets. See column 6, lines 8+; column 9, lines 9+; and column 11, lines 35+, within Wagner et al. See column 1, lines 53+ and column 2 within Hennig et al. Furthermore, Hennig et al. disclose that their biurets, derived from urea derivatives, are light in color. See examples. Additionally, it is noted that Wagner et al. disclose both amines and urea derivatives as being suitable agents for the production of biurets.
- 4. Therefore, one of ordinary skill in the art would have been motivated to utilize the nitrogen containing biuretizing agents of the secondary references in place of the amine component of Mohring et al., because one would have reasonably expected the nitrogen compounds of the primary reference and secondary references to function as equivalents, in view of the teachings within the secondary references. It has been held that it is *prima facie* obvious to substitute an equivalent component for another, where equivalency is known within the art. *In re Ruff*, 118 USPQ 343 (CCPA 1958). Furthermore, it has been held that it is *prima facie* obvious to combine components, known to be useful for the same purpose, to yield a third component to be used for the very same purpose. *In re Kerkhoven*, 205 USPQ 1069. Therefore, the position is further taken that it would have been obvious to combine known biuretizing agents, such as tertbutanol and urea, to yield a biuretizing composition suitable for producing a biuret.

Application/Control Number: 08/894,156 Page 4

Art Unit: 1711

5. Furthermore, the position is taken that it would have been obvious to substitute the claimed species, acetamide, for the formamide species set forth within column 9 of Wagner et al. It has been held that when chemical compounds have "very close" structural similarities and similar utilities, a *prima facie* case of obviousness may be made. *In re Grabiak*, (CAFC 1985) 769 F2d 729, 226 USPQ 870.

- 6. With respect to applicants' arguments concerning the claimed amounts of the stabilizer versus the amounts disclosed within Wagner et al., it is noted that this issue was discussed by the Board of Appeals; the Board Of Appeals agreed with the examiner's rationale that the amounts used within the respective processes are comparable. Despite applicants' arguments, applicants have failed to establish that the "about 40:1" (about 2.5 mole percent) quantity of Wagner et al. is not comparable to the amount claimed by applicants. Contrary to applicants' assertions, it is clear that the currently claimed quantity range of stabilizer has been considered by both the examiner and the Board of Appeals. Furthermore, the examiner has considered the comparative results; however, the position is taken that applicants have failed to establish that the claimed quantity range yields an unexpected result.
- 7. The examiner has considered applicants' discussion of the data set forth within the tables; however, the position is taken that it has not been established that the showings rise to the level of being unexpected. As aforementioned, Hennig et al. disclose that their biurets, derived from urea derivatives, are light in color; therefore, one would expect the argued color numbers.

 Furthermore, applicants have not established that quantitative increases in properties proportional

Application/Control Number: 08/894,156 Page 5

Art Unit: 1711

to increases in the amount of component utilized is indicative of an unexpected result. Lastly, it is not seen that comparative examples that lack a stabilizer, such as Comparative Example 12,

are representative of the prior art, since the prior art relies upon such a component.

8. Claims 12 and 18 are objected to as being dependent upon a rejected base claim, but

would be allowable if rewritten in independent form including all of the limitations of the base

claim and any intervening claims.

9. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time

policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR

1.136(a) will be calculated from the mailing date of the advisory action. In no event, however,

will the statutory period for reply expire later than SIX MONTHS from the mailing date of this

final action.

Any inquiry concerning this communication should be directed to R. Sergent at telephone

number (703) 308-2982.

R. Sergent

September 8, 2003